Immix Biopharma (IMMX) Stock Analysis & Winston Score

Immix Biopharma is a small clinical-stage biotechnology company focused on developing new treatments for cancer and inflammatory diseases. Its lead program is NXC-201, a CAR-T cell therapy being tested in patients with certain blood cancers, including AL amyloidosis and multiple myeloma. The company does not yet sell any approved products and is entirely focused on running clinical trials.

Immix generates no product revenue today. It funds its operations through equity raises and grants, which is typical for early-stage biotech companies. It operates primarily in the United States and is a very small company with a market cap around $500 million. The company has no approved drugs, no sales force, and no commercial infrastructure, so its entire value depends on whether NXC-201 succeeds in clinical trials and eventually wins regulatory approval — a process that carries significant risk of failure.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-20.0% YoY

YoY Growth Rate

Earnings declining

Insider Activity

20.2%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~2 years

$79M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-12.7%

Weak — -12.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial